FindTrial
Sign In

The effect of the time of imatinib treatment on the recurrence of patients with gastrointestinal stromal tumor

Effect of adjuvant treatment time of imatinib on the recurrence time of patients with gastrointestinal stromal tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045408
Enrollment
Unknown
Registered
2021-04-14
Start date
2021-04-15
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumors

Interventions

Case series:Null

Sponsors

Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: GIST was classified under the high-risk of recurrence category based on the modified National Institutes of Health (NIH) criteria.

Exclusion criteria

Exclusion criteria: 1. GIST patients with metastasis, inoperability or recurrence; 2. GIST patients treated with imatinib before surgery.

Design outcomes

Primary

MeasureTime frame
whether it recurred;recurrence time;gender;age;tumor size;tumor site;treatment duration;—

Countries

China

Contacts

Public ContactWu Xiaoting

Sichuan University

912270620@qq.com+86 13668203629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026